The FORT-2 trial is a phase 1b/2 trial of rogaratinib, an oral pan-FGFR1-4 inhibitor, plus atezolizumab compared to placebo plus atezolizumab in patients with untreated cisplatin-ineligible mUC that have a tumor with high (3+ or 4+) FGFR1 or FGFR3 mRNA expression by RNAscope. The gene discussed is FGFR1; the disease is neoplasm.